araag2/HINT huggingface dataset:
Clinical trial NCT01370707 (phase 3, status: completed)
Conditions: diabetes mellitus
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: metformin, cj-30001/cj-30002
SMILES: CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with Type 2 Diabetes Mellitus

          -  20~69 years old

          -  BMI < 30kg/m2

          -  HbA1c between 7% and 11%

          -  receiving no oral antihyperglycemic agent for more than seven days for at least 8
             weeks

          -  Willing to adhere to protocol requirements and sign a informed consent form

        Exclusion Criteria:

          -  Subjects with Type 1 Diabetes Mellitus

          -  FPG > 270mg/dL

          -  Subjects having insulin treatment

          -  Subjects with acute or chornic metaboic acidosis

          -  Subjects with cardiovascular disease

          -  Subjects with chronic GI disease

          -  Subjects with a history of substance or alchol abuse within 1 year

          -  Subjects with a history of hypersensitivity to biguanide or a-GI

          -  Subjects with hypopituitarism or hypocorticalism

          -  Subjects with cancer

          -  Subjects who take corticosteriods or plan to take corticosteroid

          -  AST and ALT > 2.5 times the upper limit of normal

          -  Creatinine level > 1.5mg/dL in male and 1.4mg/dL in female

          -  SBP > 150mmHg or DBP > 90mmHg

          -  Subjects who work the night shift

          -  Female subjects who are pregnant, breastfeeding or not using medically acceptable
             birth control

          -  Subjects who have participated in other study within 3 months

          -  Subjects judged to be unsuitable for this trial by investigator
Clinical trial NCT01139762 (phase 3, status: completed)
Conditions: benign prostatic hyperplasia, enlarged prostate
ICD codes: N40.0, N40.1, Q84.5, R59.0, R59.1, R59.9
Drugs: tadalafil, placebo, finasteride
SMILES: [H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Have not taken the following treatments within the indicated duration and agree not to
             use at any time during the study:

               -  All other Benign Prostatic Hyperplasia (BPH) therapy (including herbal
                  preparations) for at least 4 weeks prior to receiving study medication.

               -  Overactive bladder therapy (including antimuscarinics) for at least 4 weeks prior
                  to receiving study medication.

               -  Erectile Dysfunction therapy (including herbal preparations) for at least 4 weeks
                  prior to receiving study medication.

               -  Finasteride or dutasteride use at any time.

          -  Have bladder outlet obstruction as defined by a urinary peak flow rate (Qmax) of
             greater than or equal to 4 and less than or equal to 15 milliliters (mL)/second before
             receiving study drug.

          -  Have prostate enlargement measured by ultrasound at screening.

        Exclusion Criteria:

          -  Have prostate cancer, are being treated for cancer or have clinical evidence of
             prostate cancer [Prostate-specific antigen (PSA) greater than 10 nanograms/milliliter
             (ng/mL) at the start of study].

          -  Have had any of the following in the past 90 days: Heart attack, also known as a
             myocardial infarction (MI); Heart bypass surgery (called coronary artery bypass graft
             surgery); Had a procedure to open up blood vessels in the heart known as angioplasty
             or stent placement (percutaneous coronary intervention).

          -  Have problems with kidneys, liver, or nervous system

          -  Have uncontrolled diabetes

          -  Have had a stroke or a significant injury to brain or spinal cord.

          -  Have scheduled or planned surgery during the course of the study.
Clinical trial NCT00717678 (phase 3, status: completed)
Conditions: kidney transplantation, transplantation immunology, host vs graft reaction
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: prograf-xl, prograf, mmf
SMILES: CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, COC(=O)\C=C\C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has been fully informed and has signed an IRB approved informed consent form
             and is willing and able to follow study procedures

          -  Patient is a recipient of a primary or retransplanted cadaveric or non-HLA-identical
             living kidney transplant

          -  Patient must receive first oral dose of randomized study drug within 48 hours of
             transplant procedure

          -  Female patients of child bearing potential must have a negative urine or serum
             pregnancy test within 7 days prior to enrollment or upon hospitalization

        Exclusion Criteria:

          -  Patient has previously received or is receiving an organ transplant other than a
             kidney

          -  Patient has received a kidney transplant from a non-heart beating donor

          -  Patient has received an ABO incompatible donor kidney

          -  Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV)

          -  Patient has a current malignancy or a history of malignancy (within the past 5 years),
             except non-metastatic basal or squamous cell carcinoma of the skin that has been
             treated successfully

          -  Patient has significant liver disease, defined as having during the past 28 days
             continuously elevated AST (SGOT) and/or ALT (SGPT) levels greater than 3 times the
             upper value of the normal range of the investigational site

          -  Patient has an uncontrolled concomitant infection or any other unstable medical
             condition that could interfere with the study objectives

          -  Patient is currently taking or has been taking an investigational drug in the 30 days
             prior to transplant

          -  Patient is receiving everolimus or enteric coated mycophenolic acid at any time during
             the study

          -  Patient has a known hypersensitivity to tacrolimus, mycophenolate mofetil or
             corticosteroids

          -  Patient is pregnant or lactating

          -  Patient is unlikely to comply with the visits scheduled in the protocol

          -  Patient has any form of substance abuse, psychiatric disorder or a condition that, in
             the opinion of the investigator, may invalidate communication with the investigator
Clinical trial NCT00554216 (phase 3, status: completed)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: vi-0521, vi-0521, placebo matched phentermine/topiramate
SMILES: CC(C)(N)CC1=CC=CC=C1, CC(C)(N)CC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Body mass index (BMI) ≥ 35 kg/m2

          -  Informed consent

          -  70 years of age or less

          -  Triglyceride level ≤ 200 mg/dL with treatment of 0 or 1 medications

          -  Blood pressure of ≤ 140/90 mmHg with treatment of 0-2 medications for hypertension

          -  Fasting blood glucose level of ≤ 110 mg/dL

        Exclusion Criteria:

          -  Stroke/myocardial infarction (MI)/unstable cardiovascular disease within 6 months

          -  Clinically significant renal, hepatic or psychiatric disease

          -  Unstable thyroid disease or replacement therapy

          -  Nephrolithiasis

          -  Obesity of known genetic or endocrine origin

          -  Participation in a formal weight loss program or lifestyle intervention

          -  History of glaucoma or intraocular pressure

          -  Pregnancy or breastfeeding

          -  Alcohol abuse

          -  Smoking cessation within previous 3 months or plans to quit smoking during study

          -  Eating disorders

          -  Cholelithiasis within past 6 months

          -  Excluded medications

          -  Type 2 diabetes

          -  Previous bariatric surgery

          -  History of bipolar disorder or psychosis
Clinical trial NCT01626222 (phase 3, status: completed)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: exemestane, everolimus (rad001)
SMILES: CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Main Inclusion criteria:

        Metastatic or locally advanced breast cancer not amenable to curative treatment by surgery
        or radiotherapy or any other non-systemic treatment.

        Histological or cytological confirmation of estrogen receptor positive (ER+) and/or
        progesterone receptor positive (PgR+), human epidermal growth factor receptor 2 (HER2)
        negative breast cancer Postmenopausal women. Disease progression following prior therapy
        with non steroidal aromatase inhibitors (NSAI), defined as: Recurrence while on, or
        following completion of an adjuvant treatment with Letrozole or Anastrozole, or Progression
        while on or following completion of Letrozole or Anastrozole treatment for ABC/MBC.

        Radiological evidence of recurrence or progression on last systemic therapy prior to
        enrollment.

        Patients must have at least one lesion that can be accurately measured or bone lesions:
        lytic or mixed (lytic + sclerotic) in the absence of measurable disease.

        Written informed consent obtained before any screening procedure and according to local
        guidelines.

        Other protocol defined inclusion criteria apply.

        Main Exclusion criteria:

        HER2-overexpressing patients by local laboratory testing (IHC 3+ staining or in situ
        hybridization positive).

        Patients with only non-measurable lesions other than bone metastasis (e.g. pleural
        effusion, ascites etc.).

        Previous treatment with mTOR inhibitors or known hypersensitivity to mTOR inhibitors.

        Symptomatic brain or other CNS metastases. Previously treated brain metastases are allowed
        provided the patient is free of symptoms, prior radiotherapy for brain metastasis was more
        than four weeks before enrollment and the dose of corticosteroids is low (i.e. ≤ 10 mg/d
        Prednisolone equivalent) and stable for at least two weeks prior to enrollment.

        Patients with Hepatitis B or C or with a history of Hepatitis B or C. Patients unwilling to
        or unable to comply with the protocol. Other protocol defined exclusion criteria apply.
Clinical trial NCT00014586 (phase 3, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: bicalutamide, goserelin acetate
SMILES: [H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed prostate cancer

               -  T1-3, any G (any Gleason), N0 or NX

          -  High risk defined as G3 or Gleason more than 6 or PSA more than 20 ng/mL and unfit or
             unwilling to undergo local curative therapy OR

          -  Low risk defined as G1-2 or Gleason less than 7 and PSA no more than 20 ng/mL and no
             prior local curative therapy

          -  Asymptomatic (pain score of 0)

          -  PSA no more than 100 ng/mL (no more than 25 times normal)

          -  No metastatic disease by chest x-ray, bone scan (if PSA more than 10 ng/mL or 2.5
             times normal), and pelvic CT (if chance of lymph node metastases is at least 5% by
             Partin tables)

          -  No bone disease that would interfere with diagnosis of metastatic disease

        PATIENT CHARACTERISTICS:

        Age:

          -  80 and under

        Performance status:

          -  WHO 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Other:

          -  No other malignancy within the past 5 years except adequately treated basal cell skin
             cancer

          -  No psychological, personal, sociological, or geographical condition that would
             preclude study

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified
Clinical trial NCT00444925 (phase 3, status: completed)
Conditions: overactive bladder
ICD codes: N32.81
Drugs: fesoterodine fumarate, placebo, tolterodine tartrate
SMILES: CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Adult overactive bladder (OAB) patients who present with OAB symptoms, including
             urinary frequency >= 8 per day and urgency urinary incontinence >=1 per day

        Exclusion Criteria:

          -  Patients with conditions that would contraindicate for fesoterodine use, e.g,
             hypersensitivity to the active substance (fesoterodine) or to peanut or soya or any of
             the excipients, urinary retention, and gastric retention.

          -  Patients with significant hepatic and renal disease or other significant unstable
             diseases.

          -  OAB symptoms caused by neurological conditions, known pathologies of urinary tract,
             etc.
Clinical trial NCT00439244 (phase 3, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: zoledronic acid, placebo, teriparatide
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Postmenopausal (PMO) women between 45 and 89 years of age.

          -  Bone mineral density T score of -2.5 or less at femoral neck, total hip or lumbar
             spine OR

          -  Bone mineral density T score of -2.0 or less at femoral neck, total hip or lumbar
             spine with at least one documented osteoporotic vertebral fracture or a previously
             documented history of an osteoporotic clinical non-vertebral fracture not due to
             excessive trauma

        Exclusion criteria:

          -  Any prior use of strontium

          -  Any past or active kidney disease or problems with kidney function

          -  Prior treatment with any intravenous (i.v.) or oral bisphosphonate (such as but not
             limited to alendronate, risedronate and pamidronate) longer than 3 months
             consecutively. If bisphosphonate exposure is less than or equal to 3 months , a
             washout period of 1 year to randomization is required

          -  Calcium levels in blood within the normal range

          -  Normal liver function

          -  Non-osteoporotic forms of metabolic bone disease such as and not limited to Paget's
             disease of bone, osteomalacia, osteogenesis imperfecta or multiple myeloma

          -  Less than 3 evaluable lumbar (L1-L4) vertebrae for dual energy x-ray absorptiometry
             (DXA) measurement

          -  Treatment with osteoporotic therapies such as raloxifene, calcitonin or Hormone
             Replacement Therapy within 3 months of randomization

          -  Allergy or previous exposure to teriparatide

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00206167 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: budesonide/formoterol pmdi, formoterol turbuhaler
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  A clinical diagnosis of COPD with symptoms for more than 2 years.

          -  Smoking history of 10 or more pack years

          -  A history of at least one COPD exacerbation requiring a course of oral steroids and/or
             antibiotics within 1-12 months before first visit.

        Exclusion Criteria:

          -  A history of asthma

          -  Patients taking oral steroids

          -  Any significant disease or disorder that may jeopardize the safety of the patient
Clinical trial NCT01156571 (phase 3, status: completed)
Conditions: atherosclerosis, percutaneous coronary intervention, acute coronary syndrome
ICD codes: I67.2, I70.90, I70.91, I70.0, I70.1, I70.8, I25.83, Y35.312S, Y35.313S, Y35.412S, Y35.413S, Y35.812S, Y35.813S, Y35.92XS, I24.0
Drugs: cangrelor p2y12 (platelet) inhibitor, clopidogrel - 300 or 600 mg (study arm), clopidogrel 600 mg post cangrelor
SMILES: CSCCNC1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC(SCCC(F)(F)F)=N1, N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

        Patients may be included in the study if they meet all of the following criteria:

          -  Male or non-pregnant female at least 18 years of age

          -  Patients undergoing percutaneous coronary intervention (PCI):

               1. Stable angina (SA) patients with diagnostic coronary angiography within 90 days
                  prior to randomization demonstrating atherosclerosis

               2. Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) patients with
                  diagnostic coronary angiography within 72 hours prior to randomization
                  demonstrating atherosclerosis

               3. ST-segment elevation myocardial infarction (STEMI) patients (diagnostic
                  angiography not required)

          -  Provide written informed consent

        Exclusion Criteria:

        Patients will be excluded from the study if any of the following exclusion criteria apply
        prior to randomization:

          -  Receipt of any P2Y12 inhibitor at any time in the 7 days preceding randomization

          -  Eptifibatide and tirofiban usage within 12 hours preceding randomization (most recent
             dose must have been administered ≥12 hours prior to randomization)

          -  Abciximab usage within 7 days preceding randomization

          -  Receipt of fibrinolytic therapy in the 12 hours preceding randomization

          -  Increased bleeding risk: ischemic stroke within the last year or any previous
             hemorrhagic stroke; tumor, cerebral arteriovenous malformation, or intracranial
             aneurysm; recent (<1 month) trauma or major surgery (including bypass surgery);
             currently receiving warfarin; active bleeding
Clinical trial NCT00434967 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: candesartan cilexetil, hydrochlorothiazide, candesartan/hct 32/25 mg
SMILES: CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients will be eligible for enrolment into the study (Visit 1) if they fulfil all of
             the following criteria:

          -  Provision of signed Informed Consent

          -  Primary hypertension, untreated or treated with a maximum of 2 antihypertensive drugs
             (substances), which the patient and the physician are willing to withdraw at enrolment
             and replace with placebo.

          -  Mean sitting DBP 90-114 mmHg (value calculated in the eCRF) at Visits 1 and 2

          -  Patients will be eligible for randomisation (Visit 4) if they fulfil the following
             criterion:

          -  Mean sitting DBP of 90-114 mmHg (value calculated in the eCRF) at the end of the
             4-week single-blind placebo run-in period. The run-in period should not be shorter
             than 4 weeks.

        Exclusion Criteria:

          -  Pregnant or lactating women, or women of childbearing potential not practising an
             adequate method of contraception eg, intrauterine device, oral contraception or
             progesterone implant. Pregnancy must be excluded by a negative pregnancy test at Visit
             1.

          -  Secondary or malignant hypertension

          -  Sitting SBP of 180 mmHg or more

          -  Myocardial infarction, stroke, coronary bypass surgery or transient ischaemic attack
             within 6 months before enrolment

          -  Angina pectoris requiring more treatment than short-acting nitrates

          -  Chronic use of NSAIDs

          -  Aortic or mitral valve stenosis

          -  Cardiac failure requiring treatment

          -  Cardiac arrhythmia requiring treatment

          -  Gout

          -  Renal artery stenosis or kidney transplantation

          -  Intravascular volume depletion

          -  Hypersensitivity to any component of the investigational products or to any
             sulphonamide derived drugs

          -  Concomitant disease which may interfere with the assessment of the patient

          -  Past or present alcohol or drug abuse, or any condition associated with poor
             compliance that in the opinion of the investigator might affect the patient's
             participation in the study

          -  Chronic liver disease

          -  Concomitant or previous treatment with any other investigational drug within 20 days
             of enrolment

          -  Previous enrolment in the present study